Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466711 · ClinicalTrials.gov registry record · Phase 1
Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers
A Phase 1 study of Gastric Motility, sponsored by Motus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02466711 is a Phase 1 study of Gastric Motility that has completed, run by Motus Therapeutics. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02466711, a Phase 1 study of Gastric Motility, has completed, sponsored by Motus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effects of relamorelin (RM-131) on gastric volume, motor and sensory effects in healthy patients.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Relamorelin
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02466711
The ClinicalTrials.gov registry entry for NCT02466711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Motus Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric Motility appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02466711 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02466711 about?
NCT02466711 is a clinical study titled "Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers". The purpose of this study is to evaluate the effects of relamorelin (RM-131) on gastric volume, motor and sensory effects in healthy patients.
What is the current status of trial NCT02466711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-06. Estimated completion is 2015-09.
What conditions does trial NCT02466711 study?
This clinical trial studies the following conditions: Gastric Motility.
What interventions are being tested in trial NCT02466711?
The interventions under investigation include: Placebo (DRUG), Relamorelin (DRUG).
Who is sponsoring clinical trial NCT02466711?
This trial is sponsored by Motus Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02466711 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.